New Immune-Boosting combo tested in fight against tough head and neck cancers
NCT ID NCT01468896
Summary
This study is testing a combination of two drugs, cetuximab and interleukin-12 (IL-12), for people with advanced head and neck cancer that has returned, spread, or cannot be surgically removed. The first goal is to find a safe dose of IL-12 to use with cetuximab. The second goal is to see how well this drug combination works to shrink tumors by helping the body's immune system attack the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.